Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density.
OBJECTIVES
To evaluate the efficacy of raloxifene in preventing bone loss associated with long term gonadotropin-releasing hormone agonist (GnRH-a) administration.


METHODS
Twenty-two premenopausal women with severe endometriosis were treated with leuprolide acetate depot at a dosage of 3.75 mg/4 weeks, for 48 weeks. Bone mineral density (BMD) was evaluated at admission, and after 12 treatment cycles.


RESULTS
At cycle 12 of GnRH-a plus raloxifene treatment, lumbar spine, trochanter femoral neck, and Ward's BMD differed from before the treatment. A year after treatment, the lumbar spine and trochanter decreased slightly, but were not significantly different.


CONCLUSIONS
Our study shows that the administration of GnRH-a plus raloxifene in pre-menopausal women with severe endometriosis, is an effective long-term treatment to prevent bone loss.
['Cho|Young Hwa|YH|', 'Um|Mi Jung|MJ|', 'Kim|Suk Jin|SJ|', 'Kim|Soo Ah|SA|', 'Jung|Hyuk|H|']
Gonadotropin-releasing hormone agonist Endometriosis Bone mineral density Raloxifene hydrochloride